(Image caption: Membranes containing monounsaturated (left) and polyunsaturated (right) lipids after adding dynamin and endophilin. In a few seconds membranes rich in polyunsaturated lipids undergo many fissions. Credit: © Mathieu Pinot)

Lipids boost the brain

Consuming oils with high polyunsaturated fatty acid content, in particular those containing omega-3s, is beneficial for the health. But the mechanisms underlying this phenomenon are poorly known. Researchers at the Institut de Pharmacologie Moléculaire et Cellulaire (CNRS/Université Nice Sophia Antipolis), the Unité Compartimentation et Dynamique Cellulaires (CNRS/Institut Curie/UPMC), the INSERM and the Université de Poitiers investigated the effect of lipids bearing polyunsaturated chains when they are integrated into cell membranes. Their work shows that the presence of these lipids makes the membranes more malleable and therefore more sensitive to deformation and fission by proteins. These results, published on August 8, 2014 in Science, could help explain the extraordinary efficacy of endocytosis in neuron cells.

Consuming polyunsaturated fatty acids (such as omega-3 fatty acids) is good for the health. The effects range from neuronal differentiation to protection against cerebral ischemia. However the molecular mechanisms underlying these effects are poorly understood, prompting researchers to focus on the role of these fatty acids in cell membrane function.

For a cell to function properly, the membrane must be able to deform and divide into small vesicles. This phenomenon is called endocytosis. Generally, these vesicles allow the cells to encapsulate molecules and transport them. In neurons, these synaptic vesicles will act as a transmission pathway to the synapse for nerve messages. They are formed inside the cell, then they move to its exterior and fuse with its membrane, to transmit the neurotransmitters that they contain. Then they reform in less than a tenth of a second: this is synaptic recycling.

In the work published in Science, the researchers show that cell-or artificial membranes rich in polyunsaturated lipids are much more sensitive to the action of two proteins, dynamin and endophilin, which facilitate membrane deformation and fission.Other measurements in the study and in simulations suggest that these lipids also make the membranes more malleable. By facilitating the deformation and scission necessary for endocytosis, the presence of polyunsaturated lipids could explain rapid synaptic vesicle recycling. The abundance of these lipids in the brain could then represent a major advantage for cognitive function.

This work partially sheds light on the mode of action of omega-3. Considering that the body cannot synthesize them and that they can only be supplied by a suit able diet (rich in oily fish, etc.), it seems important to continue this work to understand the link between the functions performed by these lipids in the neuronal membrane and their health benefits.

(Figure 1: Axons grow and turn in response to guidance cues (arrows), which regulate endocytosis and exocytosis at the tips of growing axons. Credit: © 2014 T. Tojima et al.)

Steering the filaments of the developing brain

During brain development, nerve fibers grow and extend to form brain circuits. This growth is guided by molecular cues (Fig. 1), but exactly how these cues guide axon extension has been unclear. Takuro Tojima and colleagues from the RIKEN Brain Science Institute have now uncovered the signaling pathways responsible for turning growing nerve fibers, or axons, toward or away from guidance cues.

The researchers previously showed that axon-repelling cues act by inducing the removal of cell membrane—a process called endocytosis—from the side of the axon closest to the repulsive cue. The enzyme PIPKIγ90 is known to be involved in endocytosis in axons during certain types of synaptic activity, so the researchers investigated whether PIPKIγ90 also played a role in endocytosis during axon turning. By examining the developing brains of chicken embryos expressing an inactive form of PIPKIγ90, the researchers found that cues normally inducing endocytosis were no longer effective in repelling axon growth.

Cues that normally attract axons do so by driving membrane addition—exocytosis—on the side of the axon closest to the cue and also by suppressing endocytosis. Tojima’s team found that axons continued to be attracted to such cues even in the absence of PIPKIγ90, suggesting that PIPKIγ90 signaling is not involved in axon attraction.

The activity of PIPKIγ90 is known to be regulated by an enzyme called CDK5, a subunit of which binds to the protein kinase CaMKII. The researchers found that by inhibiting CDK5 or CaMKII, and thereby blocking the regulation of PIPKIγ90 that is needed to suppress endocytosis, endocytosis could occur in response to attractive cues.

They also found, however, that blocking CDK5 or CaMKII did not have any effect on endocytosis if the neurons expressed a mutant version of PIPKIγ90 that was unaffected by CDK5 and CaMKII signaling. As inhibitors of CDK5 or CaMKII did not alter endocytosis in response to repulsive cues, the team’s findings indicate that different signaling pathways are responsible for turning axons toward or away from guidance cues.

Additionally, Tojima and his colleagues showed that they could induce the attraction of axons toward drugs that inhibit endocytosis, suggesting that being able to control the direction of axon growth has potential therapeutic applications. “We hope our findings will aid in the development of future therapeutic strategies for rewiring neuronal networks after spinal cord injury and neurodegenerative diseases,” explains Tojima.

Yeast model reveals Alzheimer’s drug candidate and its mechanism of action

Using a yeast model of Alzheimer’s disease (AD), Whitehead Institute researchers have identified a drug that reduces levels of the toxic protein fragment amyloid-β (Aβ) and prevents at least some of the cellular damage caused when Ab accumulates in the brains of AD patients.

“We can use this yeast model to find small molecules that will address the underlying cellular pathologies of Alzheimer’s, an age-related disease whose burden will become even more significant as our population grows older,” says Kent Matlack, a former staff scientist in Whitehead Member Susan Lindquist’s lab. “We need a no-holds-barred approach to find effective compounds, and we need information about their mechanism of action quickly. Our work demonstrates that using a yeast model of Ab toxicity is a valid way to do this.”

The U.S. National Institute on Aging estimates that 5.1 million Americans may have AD, the most common form of dementia, which progressively robs patients of their memories, thinking, and reasoning skills. Research focused on the disease has been hampered by the affected cells’ location in the brain, where they cannot be studied until after an AD patient’s death. To explore the cellular processes compromised by AD, researchers in Lindquist’s lab created a yeast model, first described in the journal Science in 2011, that mimics in vivo the accumulation of Aβ that occurs in the human disease.

In the current research, which is described in this week’s issue of the journal Proceedings of the National Academy of Sciences (PNAS), a team of scientists in Lindquist’s lab used the yeast model to screen approximately 140,000 compounds to identify those capable of rescuing the cells from Aβ toxicity. One of the more promising classes of compounds has previously shown efficacy in animal models of AD and is about to complete a second phase II trial for AD. The mechanism by which the best-studied member of this class, clioquinol, targets Ab within the cell – where a large portion of it is produced in neurons – was unclear.  

“Our work in the yeast model shows that clioquinol decreases the amount of Aβ in the cells by 90%,” says Daniel Tardiff, a scientist in Lindquist’s lab. “That’s a strong decrease, and it’s dose-dependent. I’ve tested a lot of compounds before, and I’ve never seen anything as dramatic.”

Clioquinol chelates copper, meaning that it selectively binds the metal. In many AD patients, Aβ aggregates have higher concentrations of copper and other metals than normal, healthy brain tissue. Biochemical experiments also show that copper makes Aβ more toxic.

With clioquinol’s chelation capabilities in mind, Tardiff and Matlack, co-authors of the PNAS paper, tested clioquinol’s effect on Aβ-expressing cells in the presence of copper. The drug dramatically increased the degradation of Aβ in a copper-dependent manner, and even restored the cellular protein-trafficking process known as endocytosis, which is disrupted in both the yeast model and in AD-affected neurons.

“The clioquinol probably has a slightly higher affinity for copper than Aβ does, but it is not a strong enough chelator to strip the cell’s normal metalloproteins of the copper they need,” says Matlack. “From what we’ve seen in the yeast model, we think the drug pulls the copper away from Aβ. That would alter Aβ’s structure and likely make it more susceptible to degradation, thus shortening its half-life in the cell.”

The results from clioquinol in yeast and the clinical potential of closely related compounds are promising. While these compounds are not yet ready to serve as AD drugs in the clinic, the identification of an AD-relevant compound and cellular pathology – along with the Lindquist lab’s previous identification of human AD risk alleles that reduce Ab toxicity in yeast – suggests that this discovery platform will continue to yield information and lead to more compounds with equal or greater effectiveness, some of which will hopefully make a difference in human disease.

“It is important to remember that this class of compounds was shown to work in mouse models and in a limited human trial,” says Lindqust, who is also a professor of biology at MIT and an investigator of the Howard Hughes Medical Institute. “We have validated the yeast model and shown that we can find such compounds at a speed that was inconceivable before—indeed we found some compounds that look even more effective.”

How Our Nerves Keep Firing

University of Utah and German biologists discovered how nerve cells recycle tiny bubbles or “vesicles” that send chemical nerve signals from one cell to the next. The process is much faster and different than two previously proposed mechanisms for recycling the bubbles.

Researchers photographed mouse brain cells using an electron microscope after flash-freezing the cells in the act of firing nerve signals. That showed the tiny vesicles are recycled to form new bubbles only one-tenth of a second after they dump their cargo of neurotransmitters into the gap or “synapse” between two nerve cells or neurons.

“Without recycling these containers or ‘synaptic vesicles’ filled with neurotransmitters, you could move once and stop, think one thought and stop, take one step and stop, and speak one word and stop,” says University of Utah biologist Erik Jorgensen, senior author of the study in the Dec. 4 issue of the journal Nature.

“A fast nervous system allows you to think and move. Recycling synaptic vesicles allows your brain and muscles to keep working longer than a couple of seconds,” says Jorgensen, a distinguished professor of biology. “This process also may protect neurons from neurodegenerative diseases like Lou Gehrig’s disease and Alzheimer’s. So understanding the process may give us insights into treatments someday.”

A brain cell maintains a supply of 300 to 400 vesicles to send chemical nerve signals, using up to several hundred per second to release neurotransmitters, says the study’s first author, postdoctoral fellow Shigeki Watanabe.

Recycling vesicles is called “endocytosis.” Jorgensen and Watanabe named the process they observed “ultrafast endocytosis.” They showed it takes one-tenth of a second for a vesicle to be recycled, and such recycling occurs on the edge of “active zone” – the place on the end of the nerve cell where the vesicles first unload neurotransmitters into the synapse between brain cells.

“It’s like Whac-A-Mole: one vesicle goes down (fuses and unloads) and another pops up someplace else,” Jorgensen says.

Jorgensen believes ultrafast endocytosis is the most common way of recycling vesicles, but says the study doesn’t disprove two other, long-debated hypotheses:

– “Kiss-and-run endocytosis,” which supposedly takes one second, with a vesicle just “kissing” the inside of its nerve cell, dumping its neurotransmitters outside and “running” by detaching to reform a recycled vesicle in the same part of the active zone.

– Clathrin-mediated endocytosis,” which purportedly takes 20 seconds and occurs away from the active zone, at a point where a protein named clathrin assembles itself into a soccer-ball-shaped scaffold that forms a new vesicle or bubble.

Earlier this year, Jorgensen, Watanabe and colleagues published a related study in the journal eLife revealing that ultrafast endocytosis occurs in nematode worms. The new study of hippocampal brain cells from mice “tells us that mammals – and thus humans – do it the same way,” Jorgensen says. “The two papers together identify a process never previously seen – much faster than has been measured before.”

Jorgensen and Watanabe conducted the study with M. Wayne Davis, a University of Utah research assistant professor of biology; and technician Berit Söhl-Kielczynski and neuroscientists Christian Rosenmund, Benjamin Rost and Marcial Camacho-Pérez, all of Germany’s Charity University Medicine Berlin.

The study was funded by the National Institutes of Health, the European Research Council and the German Research Council. Jorgensen also is funded by his status as a Howard Hughes Medical Institute investigator and an Alexander von Humboldt Scholar.

Machine Gun Analogy for Vesicle Recycling

The process of a vesicle fusing to the nerve cell’s wall from the inside, then releasing neurotransmitters into the synapse is known as “exocytosis.” An analogy might be a bubble rising from boiling soup and releasing steam. The liquid part of the bubble fuses with the liquid in the soup, sooner or later to arise in another bubble.

The 2013 Nobel Prize in Physiology or Medicine went to three scientists who discovered key aspects of vesicle transport of cargo and exocytosis in nerve and other cells: which genes are required for vesicle transport, how vesicles deliver cargo to the correct locations, and how vesicles in brain cells release neurotransmitters to send a signal to the next brain neuron.

Jorgensen, Shigeki and colleagues studied the next step, endocytosis: how the membrane that forms vesicles (and nerve cell walls) is recycled to form new vesicles.

To illustrate the three possible mechanisms for recycling vesicles, Jorgensen compares vesicles with machine gun shells.

“You are fusing vesicles to the nerve cell membrane and expelling the neurotransmitter contents at extremely high rates,” he says. “The synapse will use up its ‘ammo’ very quickly at these rates, so the cell needs to refill the empty shells.”

Clathrin-mediated vesicle recycling is like “remaking the shell from scratch,” he says, while kiss-and-run endocytosis is like picking up every empty shell casing and refilling them one at a time.

“Ultrafast endocytosis allows the synapse to whip up all of the empty shells by the handful, fill them, and put them back in line at incredibly fast rates so the machine gun never runs out of ammo,” Jorgensen says.

Flash and Freeze for Nerve Cells in Action

Shigeki, Jorgensen and colleagues developed a method to photograph the tiny vesicles inside a nerve cell as the bubbles moved to the end of the cell, fused with the cell membrane, dumped their load of neurotransmitters into the gap or “synapse” between nerve cells, and then were recycled to reappear as new bubbles inside the nerve cell.

“We found a way to look at this process on a timescale that no one ever looked at before,” Watanabe says.

First, the researchers grew hundreds of brain cells from the mouse hippocampus – the often-studied part of the brain required for memory formation – on quarter-inch-wide sapphire disks placed in petri dishes with growth medium.

They added an algae gene to mouse brain cells that made the neurons produce an “ion channel” – basically a switch – that is stimulated by light instead of electricity. Then the brain cells were placed in a super-cold, high-pressure chamber, at 310 degrees below zero Fahrenheit and pressure 2,000 times greater than Earth’s atmosphere at sea level.

A wire cannot be routed into the chamber, which is why the cells were genetically programmed to be stimulated by light. The researchers flashed blue light on the mouse brain cells, making them “fire” neurotransmitter nerve signals. At the same time, the firing neurons were frozen with a blast of liquid nitrogen. To catch neurons in all stages of firing, the nerve cells were frozen at various times after the flash of blue light: 15, 30 and 100 milliseconds and one, three and 10 seconds.

“We built a new device to capture neurons performing fast behaviors,” Jorgensen says. “It stops all motion in the cell – even membranes in the act of fusing.

“We call it flash and freeze,” Watanabe says.

Next, the sapphire disks with neurons were put into liquid epoxy, which hardened and then were thin-sliced so the neurons could be photographed under an electron microscope. The ultrafast formation of recycled vesicles was visible.

“You see the outline of the membrane,” Jorgensen says. “You see the bubbles or vesicles in different stages of formation.”

Watanabe says about 3,000 mouse brain cell synapses were flashed, frozen and analyzed during the study. About 20 percent of the nerve cells had been fired and showed signs that nerve vesicles were being recycled.